Immunex

Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers

...gen and Wyeth Amgen and Wyeth Pharmaceuticals, a division of Wyeth, market ENBREL in North America. Wyeth markets ENBREL outside of North America. immunex Corporation, a wholly owned subsidiary of Amgen, manufactures ENBREL. Amgen discovers, develops, manufactures and delivers innovative human th...

Verathon Inc. Appoints Kendall Stever as Chief Financial Officer

...o expand our business into both new geographies and new categories of medical devices." Mr. Stever held various financial management positions at immunex from 1990 to 2003, when the company was sold to Amgen for $16 billion. As Immunex's Corporate Controller he oversaw all aspects of the Company's acco...

Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation

...echst Marion Roussel, Baxter Healthcare Corp., Baxter International Inc., Bayer Corporation, Dey, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., immunex Corporation, Pharmacia Corporation, Pharmacia & Upjohn LLC, Sicor, Inc., Gensia, Inc., Gensia Sicor Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc...

Onyx Pharmaceuticals Announces Management Changes

...oration, including vice president, North American sales for the company's biopharmaceutical division. Previously Kelley was vice president of sales at immunex Corporation and held various sales management positions at Adria Laboratories. Kelley earned his B.A. from the University of the Pacific. He is a memb...

Immunex in Medical Technology

Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR

...Amgen and Wyeth Amgen and Wyeth Pharmaceuticals, a division of Wyeth, market ENBREL in North America. Wyeth markets ENBREL outside of North America. immunex Corporation, a wholly owned subsidiary of Amgen, manufactures ENBREL. Additional information about ENBREL, including the full U.S. Prescribing Informa...

Immunex in Biological Technology

Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy

... of Amgen Ventures, and earlier as head of Corporate Development. His track record includes such notable completed transactions as the acquisitions of immunex and Tularik as well as numerous other business development efforts totaling over $15 billion in value. Before joining Amgen, Jay spent five years in ...

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

...ce President and General Manager of the Specialty Therapeutics Franchise at immunex Corporation from 1999 - 2001. In that capacity, he managed the discovery, development, manufacture and marketing for immunex oncology and neurology products. Mr. Parker received his undergradua...

Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55

...echnology rights, primarily ENBREL, related to the immunex Corporation ("Immunex") acquisition. (e) ...ed intangible asset previously acquired in the immunex acquisition. (n) To exclude the pro rata port...echnology rights, primarily ENBREL, related to the immunex acquisition. (b) To exclude the estimated imp...

Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23

...echnology rights, primarily ENBREL, related to the immunex Corporation ("Immunex") acquisition. (e) To...d intangible asset previously acquired in the immunex acquisition. (l) To exclude the impact of writin...echnology rights, primarily ENBREL, related to the immunex acquisition. (c) To exclude stock option ex...

Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing

...n internal medicine and rheumatology. Having worked in industry for 15 years, she has successfully led product development programs for PDL BioPharma, immunex Corporation (acquired by Amgen), where she led the Enbrel(R) development team for rheumatoid arthritis in adults and children through to commercializa...

Omeros Appoints David A. Mann to its Board of Directors

... executive management, finance and operations experience in the biotechnology industry. He was executive vice president and chief financial officer at immunex prior to and during its acquisition by Amgen, and held senior financial positions at the Fred Hutchinson Cancer Research Center. Mr. Mann serves on th...

Genmab A/S - Notice to Convene Annual General Meeting

... Widmer is the former Vice President and Director of Biological Sciences of immunex Corporation in Seattle. Prior to joining immunex in 1984, he was an assistant professor in Laboratory Medicine and Pathology...

VLST Corporation Announces Board and Executive Management Appointments

... Dendreon's chief scientific officer since 1995. Prior to joining Dendreon, he held various positions with Immunex Corporation, including president of immunex Manufacturing Corporation, vice president and director of development, and head of the departments of biochemistry and membrane biochemistry. At Immun...

West Coast VC Establishes Midwest Presence in Madison

...operational expertise will be valuable here in Madison, commented Gigot. Frazier was founded in Seattle 12 years ago by Alan Frazier, former CFO of immunex Corp., until recently has focused exclusively on healthcare, raising five funds worth over $750 million. But last year it started a new broader techno...